WO2006007435A1 - Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders - Google Patents
Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders Download PDFInfo
- Publication number
- WO2006007435A1 WO2006007435A1 PCT/US2005/021513 US2005021513W WO2006007435A1 WO 2006007435 A1 WO2006007435 A1 WO 2006007435A1 US 2005021513 W US2005021513 W US 2005021513W WO 2006007435 A1 WO2006007435 A1 WO 2006007435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzo
- compound
- dihydro
- dioxinyl
- group
- Prior art date
Links
- 0 C1Oc2ccccc2OC*1 Chemical compound C1Oc2ccccc2OC*1 0.000 description 4
- KGALVPYTKQIBAA-UHFFFAOYSA-N CC1Oc2ccccc2CC1 Chemical compound CC1Oc2ccccc2CC1 KGALVPYTKQIBAA-UHFFFAOYSA-N 0.000 description 2
- LSZMXZKYYCESMC-UHFFFAOYSA-N CC1COc2ccccc2OC1 Chemical compound CC1COc2ccccc2OC1 LSZMXZKYYCESMC-UHFFFAOYSA-N 0.000 description 1
- CSRUYHPJWRTHKB-UHFFFAOYSA-N CNC1Oc2ccccc2CC1 Chemical compound CNC1Oc2ccccc2CC1 CSRUYHPJWRTHKB-UHFFFAOYSA-N 0.000 description 1
- MVTNKPIKGGLNDR-UHFFFAOYSA-N NS(NCC1Oc2ccccc2CC1)(=O)=O Chemical compound NS(NCC1Oc2ccccc2CC1)(=O)=O MVTNKPIKGGLNDR-UHFFFAOYSA-N 0.000 description 1
- WRANTHLMINRHTR-SECBINFHSA-N N[C@@H]1Oc2ccccc2CC1 Chemical compound N[C@@H]1Oc2ccccc2CC1 WRANTHLMINRHTR-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
Definitions
- the present invention is directed to novel sulfamate and sulfamide derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
- Epilepsy describes a condition in which a person has recurrent seizures due to a chronic, underlying process.
- Epilepsy refers to a clinical phenomenon rather than a single disease entity, since there are many forms and causes of epilepsy.
- epilepsy is estimated at approximately 0.3 to 0.5 percent in different populations throughout the world, with the prevalence of epilepsy estimated at 5 to 10 people per 1000.
- An essential step in the evaluation and management of a patient with a seizure is to determine the type of seizure that has occurred.
- the main characteristic that distinguishes the different categories of seizures is whether the seizure activity is partial (synonymous with focal) or generalized.
- Partial seizures are those in which the seizure activity is restricted to discrete areas of the cerebral cortex. If consciousness is fully preserved during the seizure, the clinical manifestations are considered relatively simple and the seizure is termed a simple-partial seizure. If consciousness is impaired, the seizure is termed a complex-partial seizure. An important additional subgroup comprises those seizures that begin as partial seizures and then spread diffusely throughout the cortex, which are known as partial seizures with secondary generalization.
- Generalized seizures involve diffuse regions of the brain simultaneously in a bilaterally symmetric fashion. Absence or petit mal seizures are characterized by sudden, brief lapses of consciousness without loss of postural control. Atypical absence seizures typically include a longer duration in the lapse of consciousness, less abrupt onset and cessation, and more obvious motor signs that may include focal or lateralizing features.
- Generalized Tonic-clonic or grand mal seizures the main type of generalized seizures, are characterized by abrupt onset, without warning. The initial phase of the seizure is usually tonic contraction of muscles, impaired respiration, a marked enhancement of sympathetic tone leading to increased heart rate, blood pressure, and pupillary size.
- the tonic phase of the seizure typically evolves into the clonic phase, produced by the superimposition of periods of muscle relaxation on the tonic muscle contraction.
- the periods of relaxation progressively increase until the end of the ictal phase, which usually lasts no more than 1 min.
- the postictal phase is characterized by unresponsiveness, muscular flaccidity, and excessive salivation that can cause stridorous breathing and partial airway obstruction.
- Atonic seizures are characterized by sudden loss of postural muscle tone lasting 1-2 s. Consciousness is briefly impaired, but there is usually no postictal confusion.
- Myoclonic seizures are characterized by a sudden and brief muscle contraction that may involve one part of the body or the entire body. (www.harrisonsonline.com, March 29, 2001)
- Carbonic anhydrase inhibitors have been widely used in medicine, mainly as antiglaucoma and antisecretory drugs or diuretic agents, and are valuable compounds.
- systemic antiglaucoma agents such as acetazolamide
- Topiramate is a well known anticonvulsant drug that possesses single digit micromolar carbonic anhydrase inhibition, which is suspected as the cause of paresthesias noted by some patients taking topiramate.
- the present invention is directed to novel sulfamate and sulfamide derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders. More particularly, the present invention is direction to compounds of formula (I) and compounds of formula (II) as hereinafter defined. ?
- the present invention is directed to novel sulfamate derivatives, compounds of formula (I)
- R 1 and R 2 are each independently selected from the group consisting of hydrogen and lower alkyl; a is an integer from 1 to 2;
- each R 3 is independently selected form the group consisting of halogen, lower alkyl, hydroxy substituted lower alkyl, -O-(lowen alkyl), -S-(lower alkyl), nitro, cyano, amino, lower alkylamino, di(lower alkyl)amino and -C(O)O-(lower alkyl);
- R 1 and R 2 are each independently selected from the group consisting of hydrogen and lower alkyl
- R 4 is selected from the group consisting of hydrogen and lower alkyl; a is an integer from 1 to 2;
- each R 5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
- the present invention is further directed to a compound of formula (III)
- Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above.
- An illustration of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier.
- Illustrating the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.
- Exemplifying the invention is a method of treating epilepsy and related disorders in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
- Another example of the invention is the use of any of the compounds described herein in the preparation of a medicament for treating epilepsy or a related disorder, in a subject in need thereof.
- halogen shall mean chlorine, bromine, fluorine and iodine.
- alkyl whether used alone or as part of a substituent group, includes straight and branched chains.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like.
- lower when used with alkyl means a carbon chain composition of 1-4 carbon atoms.
- alkoxy shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n-hexyloxy and the like.
- substituents e.g., alkyl, aryl, etc.
- that group may have one or more substituents, preferably from one to five substituents, more preferably from one to three substituents, most preferably from one to two substituents, independently selected from the list of substituents.
- phenyl-alkyl- amino-carbonyl-alkyl refers to a group of the formula
- HPLC High Pressure Liquid Chromatography
- LAH Lithium Aluminum Hydride
- epilepsy and related disorders shall mean any disorder in which a subject (preferably a human adult, child or infant) experiences one or more seizures and / or tremors.
- Suitable examples include, but are not limited to, epilepsy (including, but not limited to, localization-related epilepsies, generalized epilepsies, epilepsies with both generalized and local seizures, and the like), seizures as a complication of a disease or condition (such as seizures associated with encephalopathy, phenylketonuria, juvenile Gaucher's disease, Lundborg's progressive myoclonic epilepsy, stroke, head trauma, stress, hormonal changes, drug use or withdrawal, alcohol use or withdrawal, sleep deprivation, and the like), essential tremor, restless limb syndrome, and the like.
- epilepsy including, but not limited to, localization-related epilepsies, generalized epilepsies, epilepsies with both generalized and local seizures, and the like
- seizures as a complication of a disease or condition such as seizures associated with encephalopathy, phenylketonuria, juvenile Gaucher's disease, Lundborg's progressive myoclonic epi
- the disorder is selected from epilepsy (regardless of type, underlying cause or origin), essential tremor or restless limb syndrome, more preferably, the disorder is epilepsy (regardless of type, underlying cause or origin) or essential tremor.
- subject refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or experiment.
- terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
- the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
- the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers
- these isomers may be separated by conventional techniques such as preparative chromatography.
- the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-D-tartaric acid and/or (+)-di-p- toluoyl-L-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the present invention includes within its scope prodrugs of the compounds of this invention.
- prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound.
- the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
- compositions comprising a compound of formula (I), a compound of formula (II) and / or a compound of formula (III) in association with a pharmaceutically acceptable carrier.
- these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- an insoluble salt of the active compound such as the decanoate salt
- the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the principle ingredient.
- a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical dilu
- preformulation compositions when referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from about 1 to about 1000 mg of the active ingredient of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- a compound of formula (I), a compound of formula (II) and / or a compound of formula (III) is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., i.v. sterile injectable formulations will be prepared using appropriate solubilizing agents.
- a unit dose would contain about 10 to about 300 mg of the active ingredient.
- the tablets contain some or all of the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.
- lactose hydrous pregelatinized starch
- microcrystalline cellulose sodium starch glycolate, magnesium stearate
- purified water carnauba wax
- hydroxypropyl methylcellulose titanium dioxide
- polyethylene glycol polyethylene glycol
- synthetic iron oxide and polysorbate 80.
- compositions comprising more than one active ingredient may be similarly prepared according to known methods.
- R 1 is selected from the group consisting of hydrogen and methyl.
- R 2 is selected from the group consisting of hydrogen and methyl.
- R 1 and R 2 are each hydrogen or R 1 and R 2 are each methyl.
- -(CH2)a- is selected from the group consisting of -CH2- and -CH 2 -CH 2 -.
- -(Ch ⁇ ) 3 - is -CH2-.
- R 4 is selected from the group consisting of hydrogen and methyl, preferably, R 4 is hydrogen.
- a is 1.
- b is an integer from 0 to 2.
- c is an integer from 0 to 2.
- b is an integer from 0 to 1.
- c is an integer from 0 to 1.
- the sum of b and c is an integer form 0 to 2, preferably an integer form 0 to 1.
- b is an integer from 0 to 2 and c is 0.
- a ring structure selected from the group consisting of 2-(chromanyl), 2-(6-chloro-2,3-dihydro- benzo[1 ,4]dioxinyl), 2-(benzo[1 ,3]dioxolyl), 2-(5-chloro-2,3-dihydro- benzo[1 ,4]dioxinyl), 2-(7-nitro-2,3-dihydro-benzo[1 ,4]dioxi'nyl), 2-(6,7-dichloro- 2,3-dihydro-benzo[1 ,4]dioxinyl), 2-(2,3-dihydro-naphtho[2,3-b][1 ,4]dioxinyl) and 2- (7-chloro-benzo[1 ,3]dioxolyl).
- a ring structure selected from the group consisting of 2-(5-chloro-2,3- dihydro-benzo[1 ,4]dioxinyl), 2-(7-nitro-2,3-dihydro-benzo[1 ,4]dioxinyl), 2-(6,7- dichloro-2,3-dihydro-benzo[1 ,4]dioxinyl) and 2-(2,3-dihydro-naphtho[2,3- b][1 ,4]dioxinyl).
- R 3 is selected from the group consisting of halogen, lower alkyl, hydroxy substituted lower alkyl, -O-(lower alkyl), nitro, cyano, amino, lower alkylamino and di(lower alkyl)amino.
- R 3 is selected from the group consisting of halogen and nitro.
- R 3 is selected from the group consisting of chloro and nitro.
- R 5 is selected from the group consisting of (II) halogen and lower alkyl.
- R 5 is selected from chloro, fluoro, bromo and methyl.
- R 3 is selected from the group consisting of halogen, nitro, cyano, amino, lower alkyl, lower alkoxy and -C(O)O-(lower alkyl).
- the stereo-center on the compound of formula (I) is in the S-configuration. In another embodiment of the present invention, the stereo-center on the compound of formula (I) is in the R- configuration.
- the stereo-center on the compound of formula (II) is in the S-configuration. In another embodiment of the present invention, the stereo-center on the compound of formula (II) is in the R- configuration.
- the compound of formula (I) is present as an enantiomerically enriched mixture, wherein the % enantiomeric enrichment (%ee) is greater than about 75%, preferably greater than about 90%, more preferably greater than about 95%, most preferably greater than about 98%.
- the compound of formula (II) is present as an enantiomerically enriched mixture, wherein the % enantiomeric enrichment (%ee) is greater than about 75%, preferably greater than about 90%, more preferably greater than about 95%, most preferably greater than about 98%.
- compounds of formula (I) wherein the MES activity at 100 mg/kg is greater than or equal to 3/5 mice.
- a suitably substituted compound of formula (V), a known compound or compound prepared by known methods is reacted with a suitably substituted compound of formula (Vl), a known compound or compound prepared by known methods, in the presence of a base such as NaH 1 TEA, DIPEA, pyridine, and the like, in an organic solvent such as DMF, DMSO, and the like, to yield the corresponding compound of formula (I).
- a base such as NaH 1 TEA, DIPEA, pyridine, and the like
- organic solvent such as DMF, DMSO, and the like
- a suitably substituted compound of formula (VII), a known compound or compound prepared by known methods is reacted with a suitably substituted compound of formula (VIII), a known compound or compound prepared by known methods, in the presence of a base such as TEA, DIPEA, pyridine, and the like, in an organic solvent such as DMF, DMSO, and the like, to yield the corresponding compound of formula (II).
- a base such as TEA, DIPEA, pyridine, and the like
- organic solvent such as DMF, DMSO, and the like
- a suitably substituted compound of formula (X), a known compound or compound prepared by known methods is reacted with a suitably substituted compound of formula (Xl), a known compound or compound prepared by known methods, in the presence of a base such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium t-butoxide, and the like, in an organic solvent such as methanol, ethanol, IPA, and the like, preferably at an elevated temperature in the range of about 5O 0 C to about 100 0 C, more preferably at about reflux temperature, to yield the corresponding compound of formula (XII).
- a base such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium methoxide, potassium t-butoxide, and the like
- organic solvent such as methanol, ethanol, IPA, and the like
- the compound of formula (XII) is reacted with a suitably selected reducing agent, such as LAH, and the like, in an organic solvent such as THF, diethyl ether, and the like, to yield the corresponding compound of formula (Va).
- a suitably selected reducing agent such as LAH, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XIII) a known compound or compound prepared by known method (for example as described in Scheme 3 above) is reacted with NH 4 OH, a known compound, optionally in an organic solvent such as acetonitrile, and the like, to yield the corresponding compound of formula (XIV).
- the compound of formula (XIV) is reacted with a suitably selected reducing agent, such as LAH, and the like, and the like, in an organic solvent such as THF, diethyl ether, and the like, to yield the corresponding compound of formula (Vila).
- a suitably selected reducing agent such as LAH, and the like, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XV) a known compound or compound prepared by known methods is reacted with 3-chloro-2- chloromethyl-propene, a known compound, in the presence of a base such as potassium carbonate, sodium carbonate, sodium bicarbonate, TEA, DIPEA, and the like, in an organic solvent such as acetonitrile, THF, dioxane, and the like, preferably at an elevated temperature in the range of about 50 0 C to about 1OO 0 C, more preferably, at about reflux temperature, to yield the corresponding compound of formula (XVI).
- the compound of formula (XVI) is reacted with borane, in an organic solvent such as THF, dioxane, and the like, to yield the corresponding compound of formula (XVII), which is preferably not isolated.
- the compound of formula (XVII) is reacted with aminosulfonic acid, preferably at an elevated temperature in the range of from about 50°C to about 100°, more preferably, at about reflux temperature, to yield the corresponding compound of formula (VIIb).
- a suitably substituted compound of formula (XVIII), a compound prepared as in Scheme 5 above, is reacted with a peroxide, such as hydrogen peroxide, and the like, in the presence of a base such as NaOH, KOH, and the like, in an organic solvent such as chloroform, DCE, DCM, and the like, to yield the corresponding compound of formula (Vb).
- a peroxide such as hydrogen peroxide, and the like
- a base such as NaOH, KOH, and the like
- organic solvent such as chloroform, DCE, DCM, and the like
- a suitably substituted compound of formula (XIX) a known compound or compound prepared by known methods, is reacted with a suitably selected reducing agent, such as LAH, and the like, in an organic solvent such as THF, diethyl ether, and the like to yield the corresponding compound of formula (Vc).
- a suitably selected reducing agent such as LAH, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XX) is reacted with NH 4 OH, in the presence of a coupling agent such as DCC, and the like, optionally in an organic solvent such as acetonitrile, and the like, to yield the corresponding compound of formula (XXI).
- the compound of formula (XXI) is reacted with a suitably selected reducing agent, such as LAH, and the like, in an organic solvent such as THF, diethyl ether, and the like, to yield the corresponding compound of formula (VIIc).
- a suitably selected reducing agent such as LAH, and the like
- organic solvent such as THF, diethyl ether, and the like
- a suitably substituted compound of formula (XXIV) wherein J 1 is a suitable leaving group such as Br, Cl, I, tosyl, mesyl, triflyl, and the like a known compound or compound prepared by known methods (for example, by activating the corresponding compound wherein J 1 is OH), is reacted with a cyanide such as potassium cyanide, sodium cyanide, and the like, in an organic solvent such as DMSO, DMF, THF, and the like, to yield the corresponding compound of formula (XXV).
- a cyanide such as potassium cyanide, sodium cyanide, and the like
- the compound of formula (XXV) is reduced according to known methods, for example by reacting with a suitable reducing agent such as LAH, borane, and the like, to yield the corresponding compound of formula (VIIe).
- a suitable reducing agent such as LAH, borane, and the like
- a suitably substituted compound of formula (XXVI), a known compound or compound prepared by known methods (for example according to the process outlined in Scheme 9 above) is activated, according to known method, to yield the corresponding compound of formula (XXVII), wherein J 2 is a suitable leaving group, such tosylate, Cl, Br, I, mesylate, triflate, and the like.
- the compound of formula (XXVII) is reacted with a phthalimide salt such as potassium phthlimide, sodium phthalimide, and the like, in an organic solvent such as DMF, DMSO, acetonitrile, and the like, preferably, at an elevated temperature in the range of from 5O 0 C to about 200 0 C, more preferably, at about reflux temperature, to yield the corresponding compound of formula (XXVIII).
- a phthalimide salt such as potassium phthlimide, sodium phthalimide, and the like
- organic solvent such as DMF, DMSO, acetonitrile, and the like
- the compound of formula (XXVI) is reacted with N 2 H 4 , a known compound, in an organic solvent such as ethanol, methanol, and the like, preferably, at an elevated temperature in the range of from about 50 0 C to about 100 0 C, more preferably, at about reflux temperature, and the like, to yield the corresponding compound of formula (VIId).
- a suitably substituted compound of formula (XXVII) wherein J 2 is CN is hydrolyzed according to known methods, for example by reacting with a suitable acid or base, to yield the corresponding compound of formula (XXIX).
- the compound of formula (XXIX) is reduced according to known methods, for example by reacting with a suitable reducing agent such as LAH, and the like, to yield the corresponding compound of formula (Ve).
- Catechol (10.26 g, 93.2 mmol), sodium methoxide (25% by weight in methanol, 40.3 g, 186 mmol), and methyl dichloroacetate (13.3 g, 93.2 mmol) were combined in dry methanol (100 ml_). The solution was heated to reflux overnight. The reaction was cooled to room temperature, acidified by addition of concentrated hydrochloric acid and then reduced in volume under vacuum to about 50 mL. Water was added and the mixture was extracted with diethyl ether (3 x 100 mL).
- Benzo[1 ,3]dioxole-2-carboxylic acid amide (5.44 g, 32.9 mmol) was dissolved in tetrahydrofuran (THF, 100 ml_). Lithium aluminum hydride (LAH, 1M in THF, 39.5 mL, 39.5 mmol) was added slowly to the solution at room temperature. The reaction was stirred at room temperature for 24 hours. Distilled water was added to destroy the excess LAH. Aqueous sodium hydroxide (3.0 M, 100 mL) was added and the solution was extracted with ethyl acetate (3 x 100 mL). The combined organic solution was washed with water and dried over MgSO 4 . The solvent was evaporated to yield C-benzo[1 ,3]dioxol- 2-yl-methylamine as a colorless oil.
- THF tetrahydrofuran
- the white solid was combined with potassium phthalimide (14.4 g, 78 mmol) in DMF (250 mL) and heated to reflux for 1 h, cooled to room temperature and poured into vigorously stirring water (1.5 L) and stirred 30 min. White solid was filtered and the solid was washed several times with water, 2% NaOH, and water again and let air dry to yield a (2S)-2-(2,3-Dihydro-benzo[1 ,4]dioxin-2- ylmethyl)-isoindole-1 ,3-dione as white powdery solid.
- Racemic 2,3-dihydro-1 ,4-benzdioxin-2-ylmethylamine (8.25 g, 5.0 mmol) and triethylamine (1.52 g, 15 mmol) were combined in DMF (10 ml_) and cooled in an ice bath as dimethylsulfamoyl chloride (1.44 g, 10 mmol) was added. The reaction mixture was then stirred for 3 hr with continued cooling. The reaction mixture was partitioned between ethyl acetate and water, and the ethyl acetate solution was washed with brine, dried (MgSO 4 ) and evaporated in vacuo to yield an oil.
- Racemic 2,3-dihydro-1 ,4-benzdioxin-2-ylmethylamine (825 mg, 5 mmol) was dissolved in ethyl formate (15 ml_), refluxed for 30 min and evaporated in vacuo to yield N-(2,3-dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-formamide as an oil.
- the DCM was separated and the aqueous phase extracted twice with DCM.
- the combined DCM phase was dried (Na 2 SC» 4 ) and evaporated in vacuo to yield an oil, which was purified with flash column chromatography (ethyl acetate) to yield an oil.
- the chroman-2-yl-methanol (1.97 g, 12 mmol) in DMF (30 mL) was cooled with an ice bath to about 0°C under argon and combined with 95% NaH (0.39 g, 15.6 mmol), then stirred for 30 min.
- Sulfamoyl chloride (2.78 g, 24 mmol) was then added and the reaction mixture was stirred for 1 h.
- the reaction mixture was diluted with ethyl acetate (100 mL) and water (100 mL). The ethyl acetate solution was separated and the aqueous phase was extracted twice with ethyl acetate.
- the white powdery solid was combined with hydrazine (1.06 g, 33 mmol) in EtOH (80 mL) and heated at reflux for 2 h, then cooled to room temperature. 1N HCI was added to adjust the reaction mixture's pH to pH 1.0 and the reaction mixture was then stirred for 15 min.
- White solid was filtered and washed with fresh EtOH (solid discarded) and the filtrate was evaporated in vacuo to a solid, which was partitioned between diethyl ether and dilute aqueous NaOH.
- (2S)-(-)-N-(2,3-Dihydro-7-nitro-benzo[1 ,4]dioxin-2-ylmethyl)-sulfamide (1.2 g, 4.15 mmol), was prepared from 4-nitrocatechol according to the process outlined in Example 4.
- the (2S)-(-)-N-(2,3-Dihydro-7-nitro-benzo[1 ,4]dioxin-2- ylmethyl)-sulfamide was then combined with 10% Pd/C in methanol (120 ml_) and shaken under hydrogen atmosphere (39 psi) at room temperature for 3 h.
- Example 4 Title compound was prepared according to the procedure described in Example 4 above, starting with 4-methylcatechol, to yield a white solid, which was recrystallized from ethyl acetate/ hexane to yield the title compound as a white solid.
- Anticonvulsant activity was determined using the MES test, run according to the procedure described in detail below. Swinyard EA, Woodhead JH, White HS, Franklin MR. Experimental selection, quantification, and evaluation of anticonvulsants. In Levy RH, et al., eds. Antiepileptic Drugs. 3 rd ed. New York: Raven Press, 1989:85-102
- CF-1 male albino mice 25-35g were fasted for 16 hours before testing. Mice were randomly selected into control and test groups, with the animals dosed with vehicle or test compound, at varying concentrations, respectively. On the study date, at 30 minutes prior to shock, the mice were orally dosed with vehicle (0.5% methylcellulose) or test compound (100-300 mg/kg). Seizures were induced by trans-comeal electric shock using a 60-Hz alternating current, 50 mA, delivered for 0.2 sec. The mice in the test groups were subjected to electrical stimulus at time intervals between 15 minutes and 4 hours following administration of test compound. The shock resulted in an immediate full body tonic extension. The test was complete when the entire course of the convulsion has been observed (typically, less than 1 minute after electrical stimulation), and the mice were then immediately euthanized by carbon dioxide inhalation.
- the ED 50 value of the test compound (calculated when appropriate) was the calculated dose required to block the hind limb tonic- extensor component of the MES-induced seizure in 50% of the rodents tested. A probit analysis was used to calculate the ED50 and 95% fiducial limits (FL).
- an oral composition 100 mg of the Compound #8 prepared as in Example 7 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077000922A KR101198831B1 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
EA200700035A EA013685B1 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epileppsy and related disorders |
MXPA06014934A MXPA06014934A (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders. |
ES05763399.2T ES2573844T3 (en) | 2004-06-16 | 2005-06-16 | Sulfamide and sulfamate derivatives for the treatment of epilepsy and related disorders |
CA2570606A CA2570606C (en) | 2004-06-16 | 2005-06-16 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
UAA200613517A UA91680C2 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
JP2007516788A JP4884378B2 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for treating epilepsy and related diseases |
BRPI0512242-2A BRPI0512242A (en) | 2004-06-16 | 2005-06-16 | sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
CN2005800274918A CN101006072B (en) | 2004-06-16 | 2005-06-16 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
AU2005262496A AU2005262496B2 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
NZ552056A NZ552056A (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
EP05763399.2A EP1768970B1 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
IL180108A IL180108A (en) | 2004-06-16 | 2006-12-14 | Sulfamate and sulfamide derivatives, pharmaceutical compositions containing them, processes for their preparation and uses thereof |
NO20070081A NO20070081L (en) | 2004-06-16 | 2007-01-05 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58017804P | 2004-06-16 | 2004-06-16 | |
US60/580,178 | 2004-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006007435A1 true WO2006007435A1 (en) | 2006-01-19 |
Family
ID=34972935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/021513 WO2006007435A1 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
Country Status (22)
Country | Link |
---|---|
US (1) | US8084490B2 (en) |
EP (1) | EP1768970B1 (en) |
JP (2) | JP4884378B2 (en) |
CN (1) | CN101006072B (en) |
AR (2) | AR049398A1 (en) |
AU (1) | AU2005262496B2 (en) |
BR (1) | BRPI0512242A (en) |
CA (1) | CA2570606C (en) |
CR (1) | CR8858A (en) |
EA (1) | EA013685B1 (en) |
EC (1) | ECSP067093A (en) |
ES (1) | ES2573844T3 (en) |
IL (1) | IL180108A (en) |
MX (1) | MXPA06014934A (en) |
MY (1) | MY147767A (en) |
NI (1) | NI200600306A (en) |
NO (1) | NO20070081L (en) |
NZ (1) | NZ552056A (en) |
TW (1) | TWI361691B (en) |
UA (1) | UA91680C2 (en) |
WO (1) | WO2006007435A1 (en) |
ZA (1) | ZA200700430B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007075752A1 (en) * | 2005-12-19 | 2007-07-05 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
WO2007075751A1 (en) * | 2005-12-19 | 2007-07-05 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
WO2007092086A2 (en) * | 2005-12-19 | 2007-08-16 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
WO2007075834A3 (en) * | 2005-12-19 | 2007-08-16 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of epilepsy |
WO2007095618A3 (en) * | 2006-02-15 | 2007-10-11 | Janssen Pharmaceutica Nv | Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine |
WO2007137167A2 (en) * | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
WO2009120191A1 (en) * | 2008-03-26 | 2009-10-01 | Janssen Pharmaceutica N.V. | Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide |
WO2009120192A2 (en) * | 2008-03-26 | 2009-10-01 | Jassen Pharmaceutica, N.V. | Process for the preparation of benzo-fused heteroaryl derivatives |
WO2010011548A1 (en) * | 2008-07-22 | 2010-01-28 | Janssen Pharmaceutica Nv | Novel substituted sulfamide derivatives |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8492372B2 (en) | 2008-04-29 | 2013-07-23 | Integrated Research Laboratories Sweden Ab | Modulators of dopamine neurotransmission |
US8524766B2 (en) | 2008-04-29 | 2013-09-03 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
CN101374513B (en) * | 2005-12-19 | 2013-11-27 | 詹森药业有限公司 | Use of benzo-fused heterocycle sulfamide derivatives for preparing drugs of treatment of epilepsy |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
USRE48162E1 (en) | 2015-09-17 | 2020-08-18 | Traeger Pellet Grills, Llc | Grill handle towel bar assembly |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
WO2006023861A1 (en) * | 2004-08-24 | 2006-03-02 | Janssen Pharmaceutica N.V. | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
AR058389A1 (en) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
CA2711466A1 (en) * | 2008-01-07 | 2009-07-16 | Janssen Pharmaceutica N.V. | Process for the preparation of sulfamide derivatives |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US20110105462A1 (en) * | 2008-04-29 | 2011-05-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
EP2491014A1 (en) * | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2013045681A1 (en) | 2011-09-29 | 2013-04-04 | Janssen Pharmaceutica Nv | Improved process for the preparation of sulfamide derivatives |
WO2013049021A1 (en) | 2011-09-29 | 2013-04-04 | Janssen Pharmaceutica Nv | Process for the preparation of sulfamide derivatives |
US20140275576A1 (en) | 2013-03-13 | 2014-09-18 | Janssen Pharmaceutica Nv | Process for the preparation of (2,3-dihydro-benzo[b][1,4]dioxin-2-yl) methanol derivatives |
EP3079687B1 (en) | 2013-12-12 | 2018-02-28 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
US9937145B2 (en) | 2013-12-12 | 2018-04-10 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compound for use in preventing or treating epilepsy |
US9834535B2 (en) | 2013-12-12 | 2017-12-05 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138441A2 (en) * | 1983-09-26 | 1985-04-24 | McNeilab, Inc. | Anticonvulsant sulfamate derivatives |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US480663A (en) * | 1892-08-09 | William h | ||
US2527861A (en) * | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
BE636655A (en) * | 1962-09-14 | |||
DE1211166B (en) | 1962-11-20 | 1966-02-24 | Ciba Geigy | Process for the production of new sulfamides |
US3320314A (en) | 1964-01-22 | 1967-05-16 | Sandoz Ag | Chlorobenzyl sulfamides |
US3318952A (en) * | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
US3383414A (en) * | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
DE1542785A1 (en) | 1965-07-24 | 1970-05-06 | Bayer Ag | Insect and mite repellants |
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US3621096A (en) * | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
DE2022370A1 (en) | 1970-05-08 | 1971-12-02 | Bayer Ag | N-fluorodichloromethylthio-sulfamic acid derivatives, process for their preparation and their microbicidal and fungicidal use |
US5212326A (en) * | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
FR2479825A1 (en) * | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | BENZODIOXAN 1,4 METHOXY-2 PROPANOLAMINES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
US5194446A (en) * | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
US5192785A (en) * | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
AU651244B2 (en) * | 1991-09-19 | 1994-07-14 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol |
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5258402A (en) * | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
TW274550B (en) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
DE69434652T2 (en) | 1993-12-23 | 2007-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | ANTICONVULSIVE PSEUDOFRUCTOPYRANOSE SULFAMATE |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
JPH11501619A (en) * | 1995-02-15 | 1999-02-09 | ベアーズデン バイオ,インコーポレイテッド | Modulators of alkyl carboxy amino acid-kainate receptors |
JP3235448B2 (en) * | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | Method for producing 1,4-benzodioxane derivative |
US5998380A (en) | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
KR19990071666A (en) | 1995-11-30 | 1999-09-27 | 이경하 | Sulfamide derivatives |
AU1328197A (en) * | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
EP0906104A4 (en) | 1996-03-25 | 2003-12-10 | Lilly Co Eli | Method for treating pain |
AU3501697A (en) | 1996-06-28 | 1998-01-21 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
US5841399A (en) | 1996-06-28 | 1998-11-24 | Alliedsignal Inc. | Fault detection and exclusion used in a global positioning system GPS receiver |
AU732923B2 (en) | 1996-06-28 | 2001-05-03 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
PT920422E (en) | 1996-08-14 | 2003-03-31 | Searle & Co | CRYSTAL FORM OF 4 - [(5-METHYL-3-PHENYLISOXAZOLE-4-YL] BENZENESULFONAMIDE |
WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
CN1105559C (en) | 1996-10-08 | 2003-04-16 | 奥索·麦克尼尔药品公司 | Anticonvulsant drivs. useful in treating neuropathic pain |
US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
AU719994B2 (en) * | 1996-12-10 | 2000-05-18 | Bristol-Myers Squibb Company | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
WO1999008669A1 (en) * | 1997-08-15 | 1999-02-25 | Carolyn Ann Fairbanks | Agmatine as a treatment for neuropathic pain |
DE19742508A1 (en) * | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamide-substituted chromanes, processes for their preparation, their use as medicaments or diagnostic agents and pharmaceutical preparations containing them |
NZ505200A (en) * | 1997-12-19 | 2002-09-27 | Bayer Ag | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
UA65607C2 (en) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Pharmaceutical composition (variants) and process for its preparation |
WO1999062522A1 (en) | 1998-05-29 | 1999-12-09 | Eli Lilly And Company | Combination therapy for treatment of bipolar disorders |
EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
HUP0105154A3 (en) * | 1999-01-19 | 2004-10-28 | Ortho Mcneil Pharm Inc | Use of anticonvulsant derivatives for treating cluster headaches |
WO2000042995A2 (en) | 1999-01-21 | 2000-07-27 | Ortho-Mcneil Pharmaceutical, Inc. | Use of anticonvulsant derivatives for treating transformed migraine |
US6323236B2 (en) | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
JP2002541199A (en) * | 1999-04-08 | 2002-12-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful for lowering lipids |
US6583172B1 (en) * | 1999-04-08 | 2003-06-24 | Richard P. Shank | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
CA2369230A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
EP1181012B1 (en) | 1999-05-04 | 2004-09-15 | Keith R. Edwards | Intravenous valproate for acute treatment of migraine headache |
EP2305226B1 (en) | 1999-06-14 | 2015-05-06 | Vivus, Inc. | Combination therapy for the treatment of sleep apnea associated with obesity |
MXPA02001820A (en) * | 1999-08-20 | 2003-07-14 | Johnson & Johnson | Composition comprising a tramadol material and an anticonvulsant drug. |
FR2803848B1 (en) | 2000-01-19 | 2002-02-15 | Adir | NOVEL BENZENESULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6322503B1 (en) * | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
WO2002003984A2 (en) * | 2000-07-07 | 2002-01-17 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
DE10035227A1 (en) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
US6627653B2 (en) * | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
US7256184B2 (en) * | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
CA2434491A1 (en) * | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
CA2448160A1 (en) | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
RU2246727C2 (en) | 2003-02-12 | 2005-02-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) | Method for predicting pre-clinical stage of epilepsy |
RU2226357C1 (en) | 2003-02-12 | 2004-04-10 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева | Method for diagnosing the cases of epilepsy at preclinical development state |
WO2004092216A1 (en) | 2003-04-15 | 2004-10-28 | Trangene S.A. | Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer |
EP1615629B1 (en) | 2003-04-16 | 2009-03-18 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
JPWO2004093912A1 (en) | 2003-04-23 | 2006-07-13 | 協和醗酵工業株式会社 | Preventive and / or therapeutic agent for neutrophilic inflammatory disease |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
US6949518B1 (en) * | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
EP1664011A4 (en) | 2003-09-02 | 2009-02-25 | Merck & Co Inc | Ophthalmic compositions for treating ocular hypertension |
CN1897950A (en) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused-aryl and heteroaryl derivatives and methods of their use |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
CA2571881A1 (en) | 2004-06-22 | 2006-01-26 | Andreas P. Termin | Heterocyclic derivatives for modulation of calcium channels |
JP4948403B2 (en) | 2004-07-28 | 2012-06-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Substituted indolylalkylamino derivatives as new inhibitors of histone deacetylase |
US20060276528A1 (en) * | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
WO2006023861A1 (en) | 2004-08-24 | 2006-03-02 | Janssen Pharmaceutica N.V. | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
US8283478B2 (en) * | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US20070155827A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
AR058389A1 (en) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US20070155823A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070191452A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
US20070191474A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
TW200738669A (en) | 2006-02-22 | 2007-10-16 | Janssen Pharmaceutica Nv | Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide |
EA200870556A1 (en) * | 2006-05-19 | 2009-06-30 | Янссен Фармацевтика Н.В. | COMBINED THERAPY IN THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
TW200812574A (en) * | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
CA2711466A1 (en) | 2008-01-07 | 2009-07-16 | Janssen Pharmaceutica N.V. | Process for the preparation of sulfamide derivatives |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
CN101981023A (en) | 2008-03-26 | 2011-02-23 | 詹森药业有限公司 | Process for the preparation of benzo-fused heteroaryl derivatives |
US20090247618A1 (en) * | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
MX2010010595A (en) | 2008-03-26 | 2010-10-25 | Janssen Pharmaceutica Nv | Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-be nzodioxin-2-yl) methyl-sulfamide. |
EA018567B1 (en) * | 2008-06-23 | 2013-08-30 | Янссен Фармацевтика Нв | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)sulfamide |
-
2005
- 2005-06-14 MY MYPI20052699A patent/MY147767A/en unknown
- 2005-06-15 AR ARP050102445A patent/AR049398A1/en active IP Right Grant
- 2005-06-15 TW TW094119737A patent/TWI361691B/en not_active IP Right Cessation
- 2005-06-16 JP JP2007516788A patent/JP4884378B2/en not_active Expired - Fee Related
- 2005-06-16 WO PCT/US2005/021513 patent/WO2006007435A1/en active Application Filing
- 2005-06-16 EA EA200700035A patent/EA013685B1/en not_active IP Right Cessation
- 2005-06-16 BR BRPI0512242-2A patent/BRPI0512242A/en active Search and Examination
- 2005-06-16 US US11/154,443 patent/US8084490B2/en not_active Expired - Fee Related
- 2005-06-16 UA UAA200613517A patent/UA91680C2/en unknown
- 2005-06-16 NZ NZ552056A patent/NZ552056A/en not_active IP Right Cessation
- 2005-06-16 EP EP05763399.2A patent/EP1768970B1/en active Active
- 2005-06-16 CN CN2005800274918A patent/CN101006072B/en not_active Expired - Fee Related
- 2005-06-16 AU AU2005262496A patent/AU2005262496B2/en not_active Ceased
- 2005-06-16 ES ES05763399.2T patent/ES2573844T3/en active Active
- 2005-06-16 MX MXPA06014934A patent/MXPA06014934A/en active IP Right Grant
- 2005-06-16 CA CA2570606A patent/CA2570606C/en not_active Expired - Fee Related
-
2006
- 2006-12-14 IL IL180108A patent/IL180108A/en not_active IP Right Cessation
- 2006-12-15 NI NI200600306A patent/NI200600306A/en unknown
- 2006-12-18 EC EC2006007093A patent/ECSP067093A/en unknown
-
2007
- 2007-01-05 NO NO20070081A patent/NO20070081L/en not_active Application Discontinuation
- 2007-01-15 CR CR8858A patent/CR8858A/en not_active Application Discontinuation
- 2007-01-15 ZA ZA200700430A patent/ZA200700430B/en unknown
-
2011
- 2011-07-04 JP JP2011148530A patent/JP5416740B2/en not_active Expired - Fee Related
-
2013
- 2013-06-10 AR ARP130102038 patent/AR091400A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138441A2 (en) * | 1983-09-26 | 1985-04-24 | McNeilab, Inc. | Anticonvulsant sulfamate derivatives |
Non-Patent Citations (4)
Title |
---|
"Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
B. E. MARYANOFF ET AL.: "Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-.betas.-D-fructopyranose Sulfamate and Related Compounds", J. MED. CHEM., vol. 30, no. 5, 1987, pages 880 - 887, XP002345003 * |
B. E. MARYANOFF ET AL.: "Comparison of Sulfamate and Sulfamide Groups for the Inhibition of Carbonic Anhydrase-II by Using Topiramate as a Structural Platform", J. MED. CHEM., vol. 48, no. 6, 13 December 2004 (2004-12-13), pages 1941 - 1947, XP002345002 * |
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
EA016302B1 (en) * | 2005-12-19 | 2012-04-30 | Янссен Фармацевтика Н.В. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain (variants) |
CN101374513B (en) * | 2005-12-19 | 2013-11-27 | 詹森药业有限公司 | Use of benzo-fused heterocycle sulfamide derivatives for preparing drugs of treatment of epilepsy |
WO2007092086A3 (en) * | 2005-12-19 | 2007-09-27 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
JP2009520037A (en) * | 2005-12-19 | 2009-05-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Use of benzo-fused heterocyclic sulfamide derivatives to treat epilepsy |
WO2007075752A1 (en) * | 2005-12-19 | 2007-07-05 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
EA016892B1 (en) * | 2005-12-19 | 2012-08-30 | Янссен Фармацевтика Н.В. | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids in blood |
EA016610B1 (en) * | 2005-12-19 | 2012-06-29 | Янссен Фармацевтика Н.В. | Use of benzo-fused heterocycle sulfamide derivatives for treatment and prophylaxis of epileptogenesis |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
CN101336106B (en) * | 2005-12-19 | 2012-09-05 | 詹森药业有限公司 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
AU2006331638B2 (en) * | 2005-12-19 | 2013-08-22 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of epilepsy |
EA015392B1 (en) * | 2005-12-19 | 2011-08-30 | Янссен Фармацевтика Н.В. | Method for treatment of depression |
EA015606B1 (en) * | 2005-12-19 | 2011-10-31 | Янссен Фармацевтика Н.В. | Method of treating glucose related disorder |
WO2007092086A2 (en) * | 2005-12-19 | 2007-08-16 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
WO2007075751A1 (en) * | 2005-12-19 | 2007-07-05 | Janssen Pharmaceutica N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
WO2007075834A3 (en) * | 2005-12-19 | 2007-08-16 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of epilepsy |
WO2007095618A3 (en) * | 2006-02-15 | 2007-10-11 | Janssen Pharmaceutica Nv | Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
WO2007137167A2 (en) * | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
WO2007137167A3 (en) * | 2006-05-19 | 2008-02-28 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy |
WO2009120192A2 (en) * | 2008-03-26 | 2009-10-01 | Jassen Pharmaceutica, N.V. | Process for the preparation of benzo-fused heteroaryl derivatives |
WO2009120191A1 (en) * | 2008-03-26 | 2009-10-01 | Janssen Pharmaceutica N.V. | Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide |
WO2009120192A3 (en) * | 2008-03-26 | 2010-01-21 | Jassen Pharmaceutica, N.V. | Processes for the preparation of benzo-fused dioxin derivatives |
US8524766B2 (en) | 2008-04-29 | 2013-09-03 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
US8492372B2 (en) | 2008-04-29 | 2013-07-23 | Integrated Research Laboratories Sweden Ab | Modulators of dopamine neurotransmission |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
AU2009274266B2 (en) * | 2008-07-22 | 2014-05-15 | Janssen Pharmaceutica Nv | Novel substituted sulfamide derivatives |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
EA020050B1 (en) * | 2008-07-22 | 2014-08-29 | Янссен Фармацевтика Нв | Novel substituted sulfamide derivatives |
WO2010011548A1 (en) * | 2008-07-22 | 2010-01-28 | Janssen Pharmaceutica Nv | Novel substituted sulfamide derivatives |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
USRE48162E1 (en) | 2015-09-17 | 2020-08-18 | Traeger Pellet Grills, Llc | Grill handle towel bar assembly |
Also Published As
Publication number | Publication date |
---|---|
AR049398A1 (en) | 2006-07-26 |
JP4884378B2 (en) | 2012-02-29 |
NZ552056A (en) | 2010-08-27 |
EP1768970B1 (en) | 2016-03-09 |
US20060041008A1 (en) | 2006-02-23 |
EP1768970A1 (en) | 2007-04-04 |
AU2005262496A1 (en) | 2006-01-19 |
CN101006072A (en) | 2007-07-25 |
NI200600306A (en) | 2007-11-27 |
CA2570606A1 (en) | 2006-01-19 |
MXPA06014934A (en) | 2007-08-21 |
EA013685B1 (en) | 2010-06-30 |
NO20070081L (en) | 2007-02-26 |
UA91680C2 (en) | 2010-08-25 |
MY147767A (en) | 2013-01-31 |
EA200700035A1 (en) | 2007-06-29 |
TWI361691B (en) | 2012-04-11 |
CA2570606C (en) | 2013-04-30 |
CN101006072B (en) | 2011-10-19 |
AU2005262496B2 (en) | 2011-10-20 |
US8084490B2 (en) | 2011-12-27 |
JP2011246472A (en) | 2011-12-08 |
AR091400A2 (en) | 2015-02-04 |
JP5416740B2 (en) | 2014-02-12 |
ES2573844T3 (en) | 2016-06-10 |
IL180108A (en) | 2015-10-29 |
IL180108A0 (en) | 2007-05-15 |
ECSP067093A (en) | 2007-01-26 |
TW200611702A (en) | 2006-04-16 |
BRPI0512242A (en) | 2008-02-19 |
ZA200700430B (en) | 2008-07-30 |
CR8858A (en) | 2009-01-14 |
JP2008503487A (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2570614C (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
EP1768970B1 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
AU2006331787B2 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction | |
WO2009089210A1 (en) | Preparation of sulfamide derivatives | |
EP2150249A2 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine | |
CA2634088A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents | |
WO2009120191A1 (en) | Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide | |
CA2719402A1 (en) | Process for preparation of benzo-fused heteroaryl derivatives | |
KR101198831B1 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
KR20070021316A (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
MX2008008095A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005262496 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552056 Country of ref document: NZ Ref document number: 12006502532 Country of ref document: PH Ref document number: 180108 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2570606 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/014934 Country of ref document: MX Ref document number: 2007516788 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06128221 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2005262496 Country of ref document: AU Date of ref document: 20050616 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005262496 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005763399 Country of ref document: EP Ref document number: 2007/00430 Country of ref document: ZA Ref document number: 1020077000922 Country of ref document: KR Ref document number: 200700430 Country of ref document: ZA Ref document number: CR2007-008858 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 185/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700035 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580027491.8 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077000922 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763399 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0512242 Country of ref document: BR |